JP7009642B2 - 抗－ｖｉｓｔａ抗体及びその用途 - Google Patents

抗－ｖｉｓｔａ抗体及びその用途 Download PDF

Info

Publication number
JP7009642B2
JP7009642B2 JP2020542518A JP2020542518A JP7009642B2 JP 7009642 B2 JP7009642 B2 JP 7009642B2 JP 2020542518 A JP2020542518 A JP 2020542518A JP 2020542518 A JP2020542518 A JP 2020542518A JP 7009642 B2 JP7009642 B2 JP 7009642B2
Authority
JP
Japan
Prior art keywords
seq
light chain
heavy chain
antibody
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020542518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500068A (ja
Inventor
ユンエ イ
サン スン ビュン
ジュン ミン ハ
スンホ アン
クンヒ オ
ウォン スプ イ
ミ ジュ パク
ウン ヒ イ
ド－ユン キム
ジン－サン ユ
Original Assignee
ファーマブシン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマブシン インコーポレイテッド filed Critical ファーマブシン インコーポレイテッド
Publication of JP2021500068A publication Critical patent/JP2021500068A/ja
Application granted granted Critical
Publication of JP7009642B2 publication Critical patent/JP7009642B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020542518A 2017-10-20 2018-10-22 抗－ｖｉｓｔａ抗体及びその用途 Active JP7009642B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2017-0136632 2017-10-20
KR20170136632 2017-10-20
PCT/KR2018/012494 WO2019078699A2 (fr) 2017-10-20 2018-10-22 Anticorps anti-vista et son utilisation

Publications (2)

Publication Number Publication Date
JP2021500068A JP2021500068A (ja) 2021-01-07
JP7009642B2 true JP7009642B2 (ja) 2022-01-25

Family

ID=66173724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542518A Active JP7009642B2 (ja) 2017-10-20 2018-10-22 抗－ｖｉｓｔａ抗体及びその用途

Country Status (12)

Country Link
US (1) US11407833B2 (fr)
EP (1) EP3699193A4 (fr)
JP (1) JP7009642B2 (fr)
KR (1) KR102281405B1 (fr)
CN (1) CN111465617B (fr)
AU (1) AU2018351418B2 (fr)
BR (1) BR112020007755A2 (fr)
CA (1) CA3079652C (fr)
MX (1) MX2020005495A (fr)
RU (1) RU2750723C1 (fr)
SG (1) SG11202003585VA (fr)
WO (1) WO2019078699A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
PE20210687A1 (es) 2018-07-11 2021-04-08 Bristol Myers Squibb Co Anticuerpos de union a vista a ph acido
US10577424B1 (en) * 2019-08-15 2020-03-03 Beijing Mabworks Biotech Co., Ltd. Antibodies binding VISTA and uses thereof
JP2025529280A (ja) * 2022-09-05 2025-09-04 シクリッド インコーポレイテッド 抗ｖｉｓｔａモノクローナル抗体及びその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016207717A1 (fr) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anticorps et fragments anti-vista
JP2017502667A (ja) 2013-12-24 2017-01-26 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ抗体および断片
WO2017181109A1 (fr) 2016-04-15 2017-10-19 Michael Molloy Anticorps anti-vista humain et leur utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
ATE114723T1 (de) 1987-03-02 1994-12-15 Enzon Lab Inc Organismus als träger für ''single chain antibody domain (scad)''.
WO1988007086A1 (fr) 1987-03-20 1988-09-22 Creative Biomolecules, Inc. Sequences d'amorce pour la production de proteines recombinantes
EP0305500B1 (fr) 1987-03-20 1994-11-09 Creative Biomolecules, Inc. Procede de purification de polypeptides recombinants
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
BR112015029395A2 (pt) * 2013-05-24 2017-09-19 Medimmune Llc Anticorpos anti-b7-h5 e seus usos
CN105813654B (zh) * 2013-10-11 2019-05-31 美国政府(由卫生和人类服务部的部长所代表) Tem8抗体及其用途
JOP20150008B1 (ar) * 2014-11-26 2021-08-17 Janssen Pharmaceutica Nv أجسام مضادة ل vista وأجزاء منها
JP6800853B2 (ja) 2014-12-11 2020-12-16 ピエール、ファーブル、メディカマン 抗ｃ１０ｏｒｆ５４抗体およびその使用
CA2988397A1 (fr) * 2015-05-08 2016-11-17 Eureka Therapeutics, Inc. Constructions ciblant les complexes mhc/peptide hpv16-e7 et leurs utilisations
WO2017175058A1 (fr) * 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anticorps anti-vista et fragments de ceux-ci, leurs utilisations et leurs procédés d'identification

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502667A (ja) 2013-12-24 2017-01-26 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ抗体および断片
WO2016207717A1 (fr) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anticorps et fragments anti-vista
WO2017181109A1 (fr) 2016-04-15 2017-10-19 Michael Molloy Anticorps anti-vista humain et leur utilisation

Also Published As

Publication number Publication date
AU2018351418B2 (en) 2021-08-26
SG11202003585VA (en) 2020-05-28
JP2021500068A (ja) 2021-01-07
KR102281405B1 (ko) 2021-07-26
EP3699193A4 (fr) 2022-01-26
AU2018351418A1 (en) 2020-05-14
WO2019078699A2 (fr) 2019-04-25
US20200407449A1 (en) 2020-12-31
CN111465617B (zh) 2023-08-25
RU2750723C1 (ru) 2021-07-01
CN111465617A (zh) 2020-07-28
CA3079652A1 (fr) 2019-04-25
EP3699193A2 (fr) 2020-08-26
MX2020005495A (es) 2021-01-08
US11407833B2 (en) 2022-08-09
WO2019078699A3 (fr) 2019-06-06
CA3079652C (fr) 2022-07-19
BR112020007755A2 (pt) 2020-10-20
KR20190044563A (ko) 2019-04-30

Similar Documents

Publication Publication Date Title
JP6925421B2 (ja) プログラム化された細胞死蛋白質リガンド−１（ｐｄ−ｌ１）に対する抗体及びその用途
JP7009642B2 (ja) 抗－ｖｉｓｔａ抗体及びその用途
JP7393337B2 (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
TWI902657B (zh) 結合物件(三)
EP3405494A1 (fr) Compositions d'anticorps anti-ror2 et procédés associés
CN110049998B (zh) 抗程序性细胞死亡1(pd-1)的抗体及其用途
US11407834B2 (en) Anti-PD-L1 antibody and use thereof
JP2025157457A (ja) Ｐｄ－ｌ１及びｃｄ４７に対する二重特異性単一ドメイン抗体及びその用途
TW202208438A (zh) 抗ｌｉｌｒｂ１抗體或其抗原結合片段、製備其的方法、藥物組成物、核酸分子、重組載體以及重組細胞
EP4506360A1 (fr) Anticorps anti-pvrig, composition pharmaceutique et utilisation associées
EP4435010A1 (fr) Anticorps bispécifique contre tigit et pd-l1, composition pharmaceutique de celui-ci et son utilisation
CA3229113A1 (fr) Anticorps bispecifiques anti-b7-h4/anti-4-1bb et leurs utilisations
KR20220068984A (ko) 항-bcma 항체, 이의 항원-결합 단편 및 이의 의학적 용도
CN114341170A (zh) 一种人源化抗vegfr2抗体及其应用
KR20230163305A (ko) Pd-l1 및 cd47에 대한 이중특이적 인간화 단일 도메인 항체 및 이의 용도
WO2023103962A1 (fr) Molécule de liaison à tnfr2 et son utilisation
CN116234559A (zh) 抗cd22单结构域抗体和治疗性构建体
EP4722249A1 (fr) Anticorps anti-cd200r1 et son utilisation
AU2024305430A1 (en) Antibody binding to human ccr8 and the use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210824

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220112

R150 Certificate of patent or registration of utility model

Ref document number: 7009642

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250